NVSTNYSEDental Equipment & SuppliesFiscal year ends December 31
Envista Holdings Corp
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 5, 2026
$22.61−0.29 (-1.27%)
Close on Oct 19, 2026
- Market cap
- $3.71B
- P/E (TTM)
- 39.0
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
190M of 161M shares
Institutional holders
382
51 new, 56 sold out
Net institutional buying
12M
In Q2 2026
Insider trades, 12 months
0 buys · 3 sales
Net sold $510.25K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Dimensional Fund Advisors LP | 9,170,511 | 5.40% | 13G (passive) | Jun 30, 2025 |
| Vanguard Capital Management | 8,574,557 | 5.23% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 15,864,543 | 9.20% | 13G (passive) amendment | Mar 31, 2025 |
| Ariel Investments, LLC | 11,359,999 | 6.60% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NVST | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 18,437,542 | 11.48% | $485.83M | +584,715 | 0.01% |
| Ariel Investments, LLC | 9,818,177 | 6.11% | $258.71M | −1,045,415 | 2.58% |
| Dimensional Fund Advisors LP | 9,566,949 | 5.96% | $252.10M | −213,999 | 0.05% |
| Vanguard Portfolio Management LLC | 7,487,670 | 4.66% | $197.30M | −79,051 | 0.01% |
| Vanguard Capital Management LLC | 7,337,916 | 4.57% | $193.35M | +19,335 | 0.00% |
| Morgan Stanley | 6,436,043 | 4.01% | $169.59M | −2,357,094 | 0.01% |
| Gates Capital Management, Inc. | 5,552,383 | 3.46% | $146.31M | +189,672 | 3.52% |
| State Street Corp | 5,329,275 | 3.32% | $140.49M | +100,517 | 0.00% |
| Alliancebernstein L.P. | 5,213,644 | 3.25% | $132.27M | +185,033 | 0.04% |
| Arrowstreet Capital, Limited Partnership | 4,847,940 | 3.02% | $127.74M | +1,989,647 | 0.06% |
| Franklin Resources Inc | 4,810,040 | 2.99% | $126.74M | −2,083,985 | 0.03% |
| Victory Capital Management Inc | 4,494,346 | 2.80% | $118.43M | +101,278 | 0.07% |
| Ilex Capital Partners (UK) LLP | 4,372,709 | 2.72% | $115.22M | New | 2.36% |
| Quantinno Capital Management LP | 4,194,886 | 2.61% | $110.54M | +1,499,916 | 0.13% |
| Aqr Capital Management LLC | 4,023,691 | 2.51% | $106.02M | +1,405,574 | 0.04% |
| Neuberger Berman Group LLC | 3,876,747 | 2.41% | $102.15M | +3,864,108 | 0.07% |
| Fuller & Thaler Asset Management, Inc. | 3,642,097 | 2.27% | $95.97M | −131,655 | 0.26% |
| JPMorgan Chase & Co | 3,304,946 | 2.06% | $89.50M | +388,702 | 0.00% |
| Geode Capital Management, LLC | 3,150,508 | 1.96% | $83.04M | +1,213 | 0.00% |
| American Century Companies Inc | 3,052,519 | 1.90% | $80.43M | −149,107 | 0.04% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 382 | 190M | 100.0% | 51 / 147 | 130 / 56 | 33M | 21M |
| Q1 2026 | 392 | 178M | 100.0% | 95 / 130 | 120 / 32 | 37M | 28M |
| Q4 2025 | 337 | 186M | 100.0% | 65 / 116 | 114 / 37 | 21M | 26M |
| Q3 2025 | 312 | 191M | 100.0% | 59 / 105 | 103 / 28 | 14M | 23M |
| Q2 2025 | 285 | 200M | 100.0% | 45 / 92 | 119 / 47 | 20M | 15M |
| Q1 2025 | 289 | 195M | 100.0% | 44 / 115 | 89 / 41 | 23M | 23M |
| Q4 2024 | 291 | 195M | 100.0% | 39 / 88 | 122 / 42 | 20M | 23M |
| Q3 2024 | 298 | 198M | 100.0% | 53 / 104 | 106 / 46 | 42M | 19M |
| Q2 2024 | 292 | 194M | 100.0% | 29 / 136 | 100 / 38 | 30M | 58M |
| Q1 2024 | 302 | 223M | 100.0% | 41 / 119 | 115 / 57 | 46M | 27M |
| Q4 2023 | 319 | 204M | 100.0% | 77 / 144 | 71 / 69 | 60M | 31M |
| Q3 2023 | 316 | 176M | 100.0% | 43 / 116 | 124 / 45 | 15M | 21M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NVST | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 5,573,255 | 3.47% | $146.86M | 0.12% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 5,158,976 | 3.21% | $135.94M | 0.01% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,733,859 | 2.32% | $98.39M | 0.05% | Jun 30, 2026 |
| Eaton Vance Atlanta Capital SMID-Cap Fund | 3,389,824 | 2.11% | $89.32M | 1.02% | Jun 30, 2026 |
| Ariel Fund | 3,384,359 | 2.11% | $89.18M | 3.08% | Jun 30, 2026 |
| Undiscovered Managers Behavioral Value Fund | 2,983,701 | 1.86% | $78.62M | 0.87% | Jun 30, 2026 |
| Franklin Small Cap Value Fund | 2,570,956 | 1.60% | $70.21M | 1.64% | Jul 31, 2026 |
| Vanguard Small-Cap Value Index Fund | 2,364,068 | 1.47% | $62.29M | 0.09% | Jun 30, 2026 |
| U.S. Small Cap Value Portfolio | 2,235,061 | 1.39% | $61.04M | 0.31% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,865,888 | 1.16% | $49.17M | 0.05% | Jun 30, 2026 |
| BlackRock Event Driven Equity Fund | 1,728,308 | 1.08% | $40.70M | 0.85% | May 29, 2026 |
| Mid Cap Value Fund | 1,574,304 | 0.98% | $41.48M | 0.73% | Jun 30, 2026 |
| JPMorgan Small Cap Equity Fund | 1,520,560 | 0.95% | $40.07M | 1.39% | Jun 30, 2026 |
| Victory Sycamore Small Company Opportunity Fund | 1,500,000 | 0.93% | $39.53M | 0.84% | Jun 30, 2026 |
| MFS Blended Research Mid Cap Equity Fund | 1,333,961 | 0.83% | $31.41M | 1.07% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul A. Keel | Chief Executive Officer, Director | 551,304 | 0.34% | Aug 20, 2026 |
| Robert Befidi | President, Diagnostics | 45,785 | 0.03% | Aug 27, 2026 |
| Veronica Acurio | President, Orthodontics | 48,806 | 0.03% | Aug 27, 2026 |
| Eric D. Hammes | Chief Financial Officer | 99,913 | 0.06% | Aug 27, 2026 |
| Stefan Nilsson | President, Nobel Biocare | 61,560 | 0.04% | Aug 27, 2026 |
| Mischa Reis | SVP, Strategy & Bus. Dev. | 27,321 | 0.02% | Aug 24, 2026 |
| Coree K. Thomas | CAO | 2,535 | 0.00% | Aug 13, 2026 |
| Faez C. Kaabi | Chief Accounting Officer | 58,552 | 0.04% | Feb 27, 2026 |
| Mark E. Nance | General Counsel | 68,577 | 0.04% | Feb 27, 2026 |
| Daniel Raskas | Director | 54,010 | 0.03% | May 21, 2026 |
| Christine A. Tsingos | Director | 59,930 | 0.04% | May 21, 2026 |
| Vivek Jain | Director | 52,945 | 0.03% | May 21, 2026 |
| Wendy Carruthers | Director | 59,940 | 0.04% | May 21, 2026 |
| R. Scott Huennekens | Director | 82,105 | 0.05% | May 21, 2026 |
| Kieran Gallahue | Director | 54,010 | 0.03% | May 21, 2026 |
| James Andrew Pierce | Director | 18,485 | 0.01% | May 21, 2026 |
| Barbara B. Hulit | Director | 79,820 | 0.05% | Jun 12, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Stefan Nilsson President, Nobel Biocare | Aug 25, 2026 | Tax withholding | −804 | $27.47 | $22.09K | 61,560 |
| Veronica Acurio President, Orthodontics | Aug 25, 2026 | Tax withholding | −7,710 | $27.47 | $211.79K | 48,806 |
| Robert Befidi President, Diagnostics | Aug 25, 2026 | Tax withholding | −5,147 | $27.47 | $141.39K | 45,785 |
| Eric D. Hammes Chief Financial Officer | Aug 25, 2026 | Tax withholding | −10,885 | $27.47 | $299.01K | 99,913 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Aug 20, 2026 | Sale(10b5-1 plan) | −8,000 | $27.50 | $220.00K | 27,321 |
| Paul A. Keel Chief Executive Officer, Director | Aug 18, 2026 | Award | +179,730 | – | – | 551,304 |
| Paul A. Keel Chief Executive Officer, Director | May 25, 2026 | Tax withholding | −12,811 | $23.43 | $300.16K | 371,574 |
| Vivek Jain Director | May 19, 2026 | Award | +9,330 | – | – | 52,945 |
| R. Scott Huennekens Director | May 19, 2026 | Award | +12,585 | – | – | 82,105 |
| James Andrew Pierce Director | May 19, 2026 | Award | +9,330 | – | – | 18,485 |
| Kieran Gallahue Director | May 19, 2026 | Award | +9,330 | – | – | 54,010 |
| Wendy Carruthers Director | May 19, 2026 | Award | +9,330 | – | – | 59,940 |
| Daniel Raskas Director | May 19, 2026 | Award | +9,330 | – | – | 54,010 |
| Christine A. Tsingos Director | May 19, 2026 | Award | +9,330 | – | – | 59,930 |
| Faez C. Kaabi Chief Accounting Officer | Feb 25, 2026 | Award | +13,520 | – | – | 58,552 |
| Faez C. Kaabi Chief Accounting Officer | Feb 25, 2026 | Tax withholding | −4,964 | $29.59 | $146.88K | 45,032 |
| Eric D. Hammes Chief Financial Officer | Feb 25, 2026 | Award | +16,055 | – | – | 110,798 |
| Eric D. Hammes Chief Financial Officer | Feb 25, 2026 | Tax withholding | −2,045 | $29.59 | $60.51K | 94,743 |
| Veronica Acurio President, Orthodontics | Feb 25, 2026 | Award | +7,605 | – | – | 56,516 |
| Veronica Acurio President, Orthodontics | Feb 25, 2026 | Tax withholding | −1,412 | $29.59 | $41.78K | 48,911 |
| Mark E. Nance General Counsel | Feb 25, 2026 | Tax withholding | −3,368 | $29.59 | $99.66K | 68,577 |
| Mark E. Nance General Counsel | Feb 25, 2026 | Award | +12,675 | – | – | 81,252 |
| Robert Befidi President, Diagnostics | Feb 25, 2026 | Award | +7,605 | – | – | 50,932 |
| Robert Befidi President, Diagnostics | Feb 25, 2026 | Tax withholding | −2,177 | $29.59 | $64.42K | 43,327 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 25, 2026 | Award | +5,915 | – | – | 35,321 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 25, 2026 | Tax withholding | −2,976 | $29.59 | $88.06K | 29,406 |
| Stefan Nilsson President, Nobel Biocare | Feb 25, 2026 | Award | +7,605 | – | – | 62,364 |
| Stefan Nilsson President, Nobel Biocare | Feb 25, 2026 | Tax withholding | −182 | $29.59 | $5.39K | 54,759 |
| Paul A. Keel Chief Executive Officer, Director | Feb 25, 2026 | Tax withholding | −11,840 | $29.59 | $350.35K | 335,715 |
| Paul A. Keel Chief Executive Officer, Director | Feb 25, 2026 | Award | +48,670 | – | – | 384,385 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 10, 2026 | Option exercise | +5,634 | $15.97 | $89.97K | 38,016 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 10, 2026 | Option exercise | +4,041 | $19.04 | $76.94K | 36,423 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 10, 2026 | Sale(10b5-1 plan) | −4,041 | $30.00 | $121.23K | 32,382 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 10, 2026 | Sale(10b5-1 plan) | −5,634 | $30.00 | $169.02K | 32,382 |
| Paul A. Keel Chief Executive Officer, Director | Nov 1, 2025 | Tax withholding | −54,097 | $20.35 | $1.10M | 347,555 |
| Eric D. Hammes Chief Financial Officer | Aug 25, 2025 | Tax withholding | −7,654 | $21.12 | $161.65K | 96,788 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Aug 25, 2025 | Sale(10b5-1 plan) | −15,000 | $21.60 | $324.00K | 32,382 |
| Robert Befidi President, Diagnostics | Aug 25, 2025 | Tax withholding | −3,454 | $21.12 | $72.95K | 45,504 |
| Veronica Acurio President, Orthodontics | Aug 25, 2025 | Tax withholding | −5,422 | $21.12 | $114.51K | 50,323 |
| Stefan Nilsson President, Nobel Biocare | Aug 25, 2025 | Tax withholding | −804 | $21.12 | $16.98K | 54,941 |
| James Andrew Pierce Director | Jul 14, 2025 | Award | +9,155 | – | – | 9,155 |
| Wendy Carruthers Director | Jun 10, 2025 | Award | +10,450 | – | – | 50,610 |
| Daniel Raskas Director | Jun 10, 2025 | Award | +10,450 | – | – | 44,680 |
| Christine A. Tsingos Director | Jun 10, 2025 | Award | +10,450 | – | – | 50,600 |
| Vivek Jain Director | Jun 10, 2025 | Award | +10,450 | – | – | 43,615 |
| R. Scott Huennekens Director | Jun 10, 2025 | Award | +14,370 | – | – | 69,520 |
| Kieran Gallahue Director | Jun 10, 2025 | Award | +10,450 | – | – | 44,680 |
| Barbara B. Hulit Director | Jun 10, 2025 | Award | +10,450 | – | – | 79,820 |
| Paul A. Keel Chief Executive Officer, Director | May 25, 2025 | Tax withholding | −12,787 | $16.72 | $213.80K | 401,652 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 26, 2025 | Award | +8,475 | – | – | 47,382 |
| Robert Befidi President, Diagnostics | Feb 25, 2025 | Award | +10,290 | – | – | 48,958 |
| Robert Befidi President, Diagnostics | Feb 25, 2025 | Tax withholding | −1,123 | $20.66 | $23.20K | 38,668 |
| Veronica Acurio President, Orthodontics | Feb 25, 2025 | Award | +10,290 | – | – | 55,745 |
| Stefan Nilsson President, Nobel Biocare | Feb 25, 2025 | Award | +10,290 | – | – | 55,745 |
| Eric D. Hammes Chief Financial Officer | Feb 25, 2025 | Award | +15,735 | – | – | 104,442 |
| Paul A. Keel Chief Executive Officer, Director | Feb 25, 2025 | Award | +65,830 | – | – | 414,439 |
| Mischa Reis SVP, Strategy & Bus. Dev. | Feb 25, 2025 | Tax withholding | −3,813 | $20.66 | $78.78K | 38,907 |
| Faez C. Kaabi Chief Accounting Officer | Feb 25, 2025 | Tax withholding | −4,319 | $20.66 | $89.23K | 40,311 |
| Faez C. Kaabi Chief Accounting Officer | Feb 25, 2025 | Award | +9,685 | – | – | 49,996 |
| Mark E. Nance General Counsel | Feb 25, 2025 | Tax withholding | −3,691 | $20.66 | $76.26K | 53,790 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mischa Reis Officer | Aug 20, 2026 | 8,000 | $220.00K | Aug 20, 2026 | Restricted Stock Vesting |
| Mischa Reis Officer | Feb 10, 2026 | 9,675 | $290.25K | Feb 10, 2026 | Options Granted - 05/15/2017 |
| Mischa Reis Officer | Aug 25, 2025 | 15,000 | $324.00K | Aug 25, 2025 | Restricted Stock Vesting |
| Eric Conley Former Officer | Aug 6, 2024 | 12,798 | $204.83K | Aug 6, 2024 | Restricted Stock Vesting |
| Eric Conley Former Officer | Jun 21, 2024 | 9,185 | $158.65K | Jun 21, 2024 | Open Market Purchase |
| Howard H. Yu Former Officer | Oct 5, 2023 | 3,717 | $104.11K | Oct 5, 2023 | Restricted Stock Vesting |
| Howard H. Yu Former Officer | Oct 4, 2023 | 60,531 | $1.63M | Oct 4, 2023 | Option Granted - 02/24/2017 |